Cencora Inc (COR)

Schlusskurs vom Vortag:

$229.20

Offen:

$228.49

24-Stunden-Volumen:

2.01M

Marktkapitalisierung:

$44.78B

Einnahmen:

$271.58B

Nettoeinkommen (Verlust:

$1.87B

KGV:

26.35

EPS:

8.53

Netto-Cashflow:

$3.63B

1W Leistung:

-6.26%

1M Leistung:

-7.55%

6M Leistung:

-100.00%

1J Leistung:

-100.00%

1-Tages-Spanne:

$224.32

$228.79

52-Wochen-Spanne:

$215.30

$246.75

Cencora Inc Stock (COR) Company Profile

Firmenname

Cencora Inc

Sektor

Healthcare (1190)

Branche

Medical Distribution (11)

Telefon

(610) 727-7000

Adresse

1 WEST FIRST AVENUE, CONSHOHOCKEN

Mitarbeiter

46,000

Twitter

Nächster Verdiensttermin

2024-05-29

Neueste SEC-Einreichungen

COR's Discussions on Twitter

Cencora Inc Stock (COR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-03	Eingeleitet	Barclays	Overweight
2023-12-14	Eingeleitet	Wells Fargo	Equal Weight
2023-03-31	Eingeleitet	Citigroup	Buy
2023-01-31	Fortgesetzt	Evercore ISI	Outperform
2022-10-11	Hochstufung	BofA Securities	Neutral → Buy
2022-08-22	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-07-11	Herabstufung	Evercore ISI	Outperform → In-line
2022-06-07	Hochstufung	Deutsche Bank	Hold → Buy
2022-05-26	Hochstufung	Barclays	Equal Weight → Overweight
2022-04-12	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-04-01	Fortgesetzt	Credit Suisse	Outperform
2021-03-12	Fortgesetzt	Evercore ISI	In-line
2021-02-04	Hochstufung	Evercore ISI	In-line → Outperform
2021-02-02	Hochstufung	Cowen	Market Perform → Outperform
2021-01-06	Hochstufung	BofA Securities	Underperform → Neutral
2021-01-06	Hochstufung	Credit Suisse	Neutral → Outperform
2020-12-10	Herabstufung	Wells Fargo	Equal Weight → Underweight
2020-12-03	Eingeleitet	Mizuho	Neutral
2020-08-06	Hochstufung	Raymond James	Mkt Perform → Outperform
2020-07-15	Eingeleitet	Barclays	Underweight
2020-06-15	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-04-23	Fortgesetzt	Credit Suisse	Outperform
2020-04-16	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-04-13	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-04-01	Hochstufung	JP Morgan	Neutral → Overweight
2020-03-17	Hochstufung	Citigroup	Neutral → Buy
2020-02-11	Herabstufung	BofA/Merrill	Buy → Underperform
2020-02-07	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-09-12	Eingeleitet	Deutsche Bank	Hold
2019-07-10	Herabstufung	KeyBanc Capital Markets	Overweight → Sector Weight
2019-04-11	Eingeleitet	Guggenheim	Buy
2019-04-10	Herabstufung	BofA/Merrill	Buy → Underperform
2019-04-10	Herabstufung	Evercore ISI	Outperform → In-line
2019-02-11	Herabstufung	JP Morgan	Neutral → Underweight
2019-01-17	Eingeleitet	UBS	Buy
2018-12-10	Herabstufung	Jefferies	Buy → Hold
2018-10-26	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2018-09-20	Eingeleitet	Berenberg	Buy
2018-07-17	Fortgesetzt	Stifel	Hold
2018-04-09	Eingeleitet	MoffettNathanson	Buy
2018-03-12	Hochstufung	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-03-12	Hochstufung	Raymond James	Mkt Perform → Outperform
2017-09-25	Eingeleitet	JP Morgan	Neutral
2017-09-22	Eingeleitet	William Blair	Outperform

Alle ansehen

Cencora Inc Aktie (COR) Neueste Nachrichten

Unveiling 4 Analyst Insights On Cencora

Benzinga

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks Investment Research

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

Zacks Investment Research

Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised

Zacks Investment Research

Cencora (COR) Q2 Earnings Top Estimates

Zacks Investment Research

Finanzdaten der Cencora Inc-Aktie (COR)

Cencora Inc (COR) Umsatz 2024

Cencora Inc (COR) Nettogewinn 2024

Cencora Inc (COR) Free Cashflow 2024

Cencora Inc (COR) Gewinn je Aktie 2024

Cencora Inc-Aktie (COR) Insiderhandel